Vytorin study to continue after review; Merck shares jump

(Reuters) - An independent monitoring board said a large trial of Merck & Co's Vytorin cholesterol drug can continue, suggesting no major safety issues have yet been seen with the pill.

Source: Reuters: Health - March 12, 2013 Category: Consumer Health News Tags: healthNews Source Type: news